Chardan Capital Reaffirms Buy Rating for SAB Biotherapeutics (NASDAQ:SABS)

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research note issued on Friday,Benzinga reports. They currently have a $12.00 price target on the stock. Chardan Capital’s price objective suggests a potential upside of 385.83% from the stock’s previous close.

Several other analysts have also recently weighed in on SABS. HC Wainwright lowered their price target on SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Leerink Partnrs raised SAB Biotherapeutics to a “strong-buy” rating in a report on Wednesday. Finally, Leerink Partners started coverage on SAB Biotherapeutics in a report on Wednesday. They issued an “outperform” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, SAB Biotherapeutics currently has a consensus rating of “Buy” and an average price target of $9.75.

SAB Biotherapeutics Stock Performance

Shares of SABS opened at $2.47 on Friday. The stock’s 50-day simple moving average is $2.29 and its 200 day simple moving average is $1.89. The stock has a market capitalization of $25.71 million, a price-to-earnings ratio of -0.62 and a beta of 0.54. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.87 and a current ratio of 0.87. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.27). Research analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp bought a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $43,000. HB Wealth Management LLC boosted its position in shares of SAB Biotherapeutics by 10.9% during the first quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after purchasing an additional 25,800 shares in the last quarter. Finally, Silver Oak Securities Incorporated bought a new stake in shares of SAB Biotherapeutics during the first quarter valued at approximately $30,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.